Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Identifieur interne : 004338 ( PubMed/Checkpoint ); précédent : 004337; suivant : 004339Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Auteurs : A D Korczyn [Israël] ; D J Brooks ; E R Brunt ; W H Poewe ; O. Rascol ; F. StocchiSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1998.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Confidence Intervals, Disease Progression, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Female, Humans, Indoles (adverse effects), Indoles (therapeutic use), Longitudinal Studies, Male, Middle Aged, Odds Ratio, Parkinson Disease (drug therapy), Regression Analysis, Selegiline (therapeutic use), Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Bromocriptine, Dopamine Agonists, Indoles.
- chemical , therapeutic use : Antiparkinson Agents, Bromocriptine, Dopamine Agonists, Indoles, Selegiline.
- drug therapy : Parkinson Disease.
- Adult, Aged, Confidence Intervals, Disease Progression, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Longitudinal Studies, Male, Middle Aged, Odds Ratio, Regression Analysis, Severity of Illness Index, Treatment Outcome.
Abstract
We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3-year, double-blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non-selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of "responders." In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non-selegiline subgroup, there was a significantly higher proportion of "improvers" on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.
DOI: 10.1002/mds.870130112
PubMed: 9452325
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:9452325Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.</title><author><name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A D" last="Korczyn">A D Korczyn</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University</wicri:regionArea><wicri:noRegion>Tel-Aviv University</wicri:noRegion></affiliation></author><author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J" last="Brooks">D J Brooks</name></author><author><name sortKey="Brunt, E R" sort="Brunt, E R" uniqKey="Brunt E" first="E R" last="Brunt">E R Brunt</name></author><author><name sortKey="Poewe, W H" sort="Poewe, W H" uniqKey="Poewe W" first="W H" last="Poewe">W H Poewe</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Stocchi, F" sort="Stocchi, F" uniqKey="Stocchi F" first="F" last="Stocchi">F. Stocchi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9452325</idno><idno type="pmid">9452325</idno><idno type="doi">10.1002/mds.870130112</idno><idno type="wicri:Area/PubMed/Corpus">004518</idno><idno type="wicri:Area/PubMed/Curation">004518</idno><idno type="wicri:Area/PubMed/Checkpoint">004338</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.</title><author><name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A D" last="Korczyn">A D Korczyn</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University</wicri:regionArea><wicri:noRegion>Tel-Aviv University</wicri:noRegion></affiliation></author><author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J" last="Brooks">D J Brooks</name></author><author><name sortKey="Brunt, E R" sort="Brunt, E R" uniqKey="Brunt E" first="E R" last="Brunt">E R Brunt</name></author><author><name sortKey="Poewe, W H" sort="Poewe, W H" uniqKey="Poewe W" first="W H" last="Poewe">W H Poewe</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Stocchi, F" sort="Stocchi, F" uniqKey="Stocchi F" first="F" last="Stocchi">F. Stocchi</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Bromocriptine (adverse effects)</term><term>Bromocriptine (therapeutic use)</term><term>Confidence Intervals</term><term>Disease Progression</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Indoles (adverse effects)</term><term>Indoles (therapeutic use)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Parkinson Disease (drug therapy)</term><term>Regression Analysis</term><term>Selegiline (therapeutic use)</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Dopamine Agonists</term><term>Indoles</term><term>Selegiline</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Confidence Intervals</term><term>Disease Progression</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Regression Analysis</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3-year, double-blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non-selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of "responders." In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non-selegiline subgroup, there was a significantly higher proportion of "improvers" on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9452325</PMID><DateCreated><Year>1998</Year><Month>03</Month><Day>26</Day></DateCreated><DateCompleted><Year>1998</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>1998</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.</ArticleTitle><Pagination><MedlinePgn>46-51</MedlinePgn></Pagination><Abstract><AbstractText>We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3-year, double-blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non-selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of "responders." In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non-selegiline subgroup, there was a significantly higher proportion of "improvers" on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Korczyn</LastName><ForeName>A D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Brunt</LastName><ForeName>E R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Poewe</LastName><ForeName>W H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Stocchi</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>030PYR8953</RegistryNumber><NameOfSubstance UI="C046649">ropinirole</NameOfSubstance></Chemical><Chemical><RegistryNumber>14611-51-9</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>3A64E3G5ZO</RegistryNumber><NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001971">Bromocriptine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016001">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012044">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>2</Month><Day>6</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>2</Month><Day>6</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9452325</ArticleId><ArticleId IdType="doi">10.1002/mds.870130112</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Israël</li></country></list><tree><noCountry><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J" last="Brooks">D J Brooks</name><name sortKey="Brunt, E R" sort="Brunt, E R" uniqKey="Brunt E" first="E R" last="Brunt">E R Brunt</name><name sortKey="Poewe, W H" sort="Poewe, W H" uniqKey="Poewe W" first="W H" last="Poewe">W H Poewe</name><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><name sortKey="Stocchi, F" sort="Stocchi, F" uniqKey="Stocchi F" first="F" last="Stocchi">F. Stocchi</name></noCountry><country name="Israël"><noRegion><name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A D" last="Korczyn">A D Korczyn</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004338 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004338 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:9452325
|texte= Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:9452325" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |